Actuate Therapeutics (ACTU) Research & Development (2023 - 2025)
Actuate Therapeutics (ACTU) posted quarterly Research & Development of $2.1 million for Q4 2025, down 42.22% year-over-year from $3.7 million in Q4 2024, and down 2.22% quarter-over-quarter from $2.2 million in Q3 2025.
Actuate Therapeutics (ACTU) Research & Development (2023 - 2025) Analysis & Trends
Actuate Therapeutics (ACTU) has reported Research & Development for 3 consecutive years, with $2.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Research & Development fell 42.22% year-over-year to $2.1 million; the TTM figure through Dec 2025 stood at $10.3 million (down 44.89% YoY), while the FY2025 annual figure was $10.3 million, down 44.89% from the prior year.
- Research & Development eased to $2.1 million in Q4 2025 per ACTU's latest filing, from $2.2 million in the prior quarter.
- Across five years, Research & Development topped out at $6.9 million in Q1 2024 and bottomed at $2.1 million in Q4 2025.
- Historically, Research & Development has averaged $4.2 million across 3 years, with a median of $3.8 million in 2024.
- Annual changes were most pronounced in 2024 — Research & Development fell 8.47% — and 2025, when it sank 53.06%.
- Actuate Therapeutics' Research & Development stood at $6.6 million in 2023, then plunged by 44.54% to $3.7 million in 2024, then plunged by 42.22% to $2.1 million in 2025.
- Business Quant data shows ACTU's Research & Development at $2.1 million in Q4 2025, $2.2 million in Q3 2025, and $2.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 97.90 Mn |
| 10 | Actuate Therapeutics | 28.65 Mn | 28.65 Mn | - | 2.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.13 Mn |
| Sep 30, 2025 | 2.18 Mn |
| Jun 30, 2025 | 2.76 Mn |
| Mar 31, 2025 | 3.22 Mn |
| Dec 31, 2024 | 3.69 Mn |
| Sep 30, 2024 | 3.76 Mn |
| Jun 30, 2024 | 4.37 Mn |
| Mar 31, 2024 | 6.86 Mn |
| Dec 31, 2023 | 6.65 Mn |
| Sep 30, 2023 | 5.76 Mn |
| Jun 30, 2023 | 4.78 Mn |